Xortx Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: share count (0m) is 0.016x the cover-page count (7m).
Price vs value
Under review: share count (0m) is 0.016x the cover-page count (7m). We'll show the comparison once resolved.
Xortx Therapeutics Inc. valuation: adjust assumptions and compare models →
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 72% in the quarter to 2025-12-31, the 2nd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Xortx Therapeutics Inc.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 64.5% in a year.
- Heavily shorted. 13.3% of the shares available to trade are sold short (0.1 days of average volume to cover).
Latest results
- Earnings per share
- -$0.45 against an average estimate of -$1.58: beat by 71.5%
- Next report
- November 12, 2026
Price chart
- 1 day+1.0%
- 1 week-4.7%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-0.56
Growth
- Share count change
- +64.5%
Cash
- Free cash flow (TTM)
- -$2.8M
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for XRTX from the sources we follow. See filings →
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026.
Analysts' consensus
No analyst estimates are published for Xortx Therapeutics Inc.: too few analysts cover it.
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Dec 2025 | −$1.58 | −$0.45 | +71.5% |
| Sept 2025 | −$1.58 | −$1.02 | +35.2% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 13.3% of tradable shares
- Days to cover
- 0.13 at average volume
- Short interest, 1 month
- +209% to October 15, 2026
- Held by institutions
- 0% of shares
- Held by insiders
- 1.5% of shares
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities The company doesn't report a short-term split. Not assessable.
- Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +64.5%
- year over year
Who owns it
- Reported value
- $92,839
- Institutions reporting
- 6
- Shares held vs prior quarter
- ▲ 164.7%
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Citadel Advisors LLC | $52,473 | 23K | 56.5% | New |
| Stonex Group Inc. | $37,898 | 16K | 40.8% | New |
| Royal Bank Of Canada | $2,000 | 1K | 2.2% | New |
| National Bank Of Canada | $329 | 0K | 0.4% | New |
| Clearstead Advisors, LLC | $120 | 0K | 0.1% | ▼ 80.1% |
| TD Waterhouse Canada Inc. | $19 | 0K | 0.0% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Xortx Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Xortx Therapeutics Inc. in brief
- What does Xortx Therapeutics Inc. do?
- Xortx Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Xortx Therapeutics Inc.'s stock ticker?
- Xortx Therapeutics Inc. trades under the ticker XRTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Xortx Therapeutics Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Citadel Advisors LLC, Stonex Group Inc. and Royal Bank Of Canada. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- When is Xortx Therapeutics Inc.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Xortx Therapeutics Inc. announces its own schedule.
Follow research on Xortx Therapeutics Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.